HJM-561

CAT: 0804-HY-156698-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-156698-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
HJM-561 is a selective and effective orally active EGFR PROTAC degrader. HJM-561 is able to overcome the triple EGFR mutations that are resistant to Osimertinib (HY-15772) . HJM-561 exhibits potent degradation of EGFR Del19/T790M/C797S (DC50: 9.2 nM) and L858R/T790M/C797S (DC50: 5.8 nM), and has anti-tumor activity (pink: EGFR ligand (HY-12857) ; blue: CRBN ligand (HY-A0003) ; black: linker) [1].
CAS Number
[2570251-68-0]
UNSPSC
12352005
Target
EGFR; PROTACs
Type
Reference compound
Related Pathways
JAK/STAT Signaling; PROTAC; Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hjm-561.html
Purity
99.26
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C2=C(CN1C3C(NC(CC3)=O)=O)C(C#CCCN4CCN(C5CCN(CC5)C6=CC=C(C(OC)=C6)NC7=NC=C(C(NC8=C(P(C)(C)=O)C=CC=C8)=N7)Cl)CC4)=CC=C2
Molecular Formula
C45H51ClN9O5P
Molecular Weight
864.37
References & Citations
[1]Du Y, et al. HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations. Mol Cancer Ther. 2022 Jul 5;21 (7) :1060-1066.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products